Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Alnylam Pharmace. buy JPMorgan Chase & Co.

Alnylam Pharmace.
Start price
€234.00
22.07.26 / 50%
Target price
€350.68
22.07.27
Performance (%)
-15.75%
Price
€197.15
12:42
Summary
This prediction is currently active. The price of Alnylam Pharmace. has decreased since the start of the prediction. Compared to the start price this results in a performance of -15.75%. This prediction currently runs until 22.07.27. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

AI-generated
Performance without dividends (%)
Name 1w
Alnylam Pharmace. -0.279%
iShares Core DAX® -1.586%
iShares Nasdaq 100 -4.148%
iShares Nikkei 225® -6.302%
iShares S&P 500 -3.225%

Comments by JPMorgan_Chase___Co_ for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Buy
Perf. (%) -15.75%
Target price 350.680
Change
Ends at 22.07.27

Alnylam Pharmaceuticals (ALNY) had its price target lowered by JPMorgan Chase & Co. from $420.00 to $400.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat

JPMorgan Chase & Co. 
0
Report Share
22.07.26

Stopped prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€177.05
31.07.26
€325.80
31.07.27
11.35%
12:42

JPMorgan Chase & Co. 
31.07.26 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€406.80
13.10.25
€407.06
13.10.26
-51.54%
12:42

JPMorgan Chase & Co. 
13.10.25 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€277.50
16.07.25
€299.70
16.07.26
-11.71%
17.07.26

JPMorgan Chase & Co. 
16.07.25 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€264.00
12.06.25
€296.26
12.06.26
-7.54%
13.06.26

JPMorgan Chase & Co. 
12.06.25 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€270.10
24.03.25
€302.97
24.03.26
-3.00%
25.03.26

JPMorgan Chase & Co. 
24.03.25 50%